Stock Detail
VIVUS INC
Sector: Biotechnology
Latest Quote @ Fri May 5 02:46:02 (15 min delayed)
| N/A |
N/A |
$14.50 |
+0.98 |
7.25% |
6.74M |
Last Day's Data
| $14.50 |
$15.04 |
$0.98 |
7.25% |
0.00 |
$13.52 |
| $13.35 |
$13.12 |
6.00 |
1.46B |
2.48M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 16.14 |
15.32 |
14.22 |
13.40 |
12.30 |
Stock Profile
VIVUS, Inc., a pharmaceutical company, engages in the research, development, and commercialization of products to restore sexual function in women and men. Its product pipeline includes four clinical stage product candidates, including ALISTA for the treatment of female sexual arousal disorder; Testosterone-MDTS to treat hypoactive sexual desire disorder; Evamist to alleviate symptoms associated with menopause; and Avanafil, an inhibitor product candidate for the treatment of erectile dysfunction. ALISTA and Evamist are in Phase 3 trials; and Testosterone-MDTS and Avanafil are in Phase 2 trials. The company also markets MUSE, a transurethral applicator used for treating erectile dysfunction, in the United States and internationally through distribution partners. It has a development, license, and supply agreement with Tanabe Seiyaku Co., Ltd., for the development and commercialization of avanafil; and licensing agreements with Acrux Limited to develop and commercialize testosterone-MDTS and Evamist in the United States for various female health applications. VIVUS was founded by Virgil A. Place in 1991 and is headquartered in Mountain View, California.
